Approved Research Studies

To date, HCV Research UK has approved 108 applications for access to its resources. The requests since 2017 are listed below. If you require further information about these or other applications made to HCV Research UK, including details of chief investigators etc, then please contact Sarah McDonald.

Study of hepatocellular carcinoma development in patients with decompensated liver disease following onset of DAA therapy.
University of Nottingham
Approved March 2017

Are anti-ARFP antibodies a useful early biomarker for hepatocellular carcinoma development in patients with HCV infection?
University of Nottingham
Approved May 2017

Pilot assessment of the Point-of-Care Genedrive HCV NAT assay in treatment monitoring.
Genedrive, UK
Approved July 2017

Development of a novel microarray-based assay for early diagnosis of HCC.
University of Nottingham
Approved August 2017

Impact of the NS5B polymorphism A150V on HCV disease progression.
Queen Mary and Westfield College, University of London
Approved September 2017

Investigating antibody responses in individuals who spontaneously resolve hepatitis C virus.
University College London
Approved September 2017

The diversity of HCV and host genetics in African patients in the HCV Research UK cohort.
MRC-University of Glasgow Centre for Virus Research
Approved October 2017

The diversity of HCV and host genetics in African patients in the HCV Research UK cohort.
MRC-University of Glasgow Centre for Virus Research
Approved October 2017

STOP-HCV Cirrhosis Study.
University of Nottingham
Approved January 2018

Defining the clinical reference range for the Glyco Liver Profile test.
Helena Biosciences Europe, UK
Approved March 2018

Clinical validation of a HCV whole genome sequencing assay. 
Public Health England
Approved March 2018

Real-world assessment of retreatment of patients who have failed initial direct acting antiviral therapy in the UK.
Public Health England
Approved December 2018

Analysis of change in liver function and fibrosis over time in patients with advanced HCV-associated liver disease treated with DAAs: in comparison with Japanese patients with decompensated disease untreated with DAAs. 
Ogaki Woman’s College, Japan
Approved January 2019

Hepatitis C virus genotype 3 NS5A protein: resistance to direct-acting antiviral agents and functional analysis. 
University of Leeds
Approved June 2019

Hepatitis C virus genotype 3 NS5A protein: resistance to direct-acting antiviral agents and functional analysis. 
University of Leeds
Approved June 2019

Predicting hepatocellular carcinoma occurrence in patients with cirrhosis and a hepatitis C sustained viral response 
Glasgow Caledonian University
Approved September 2019

The role of compensatory changes in the HCV polyprotein on the persistence of resistance-associated substitutions following treatment with direct-acting antivirals (DAA) 
MRC-University of Glasgow Centre for Virus Research
Approved August 2019

Validation of a sanger sequencing assay for HCV genotyping. 
Viapath, King’s College Hospital, London
Approved October 2019

HCV level of detection for SVR testing. 
Boston University, USA
Approved January 2020

Evaluation of the HCV-GLUE antiviral resistance analysis tool. 
MRC-University of Glasgow Centre for Virus Research
Approved March 2020

MELD purgatory in patients with chronic HCV and treatment with DAAs. 
Toronto Centre for Liver Disease, Canada
Approved May 2020

Validation of serology tests for SARS-CoV-2 infection in the community 
MRC-University of Glasgow Centre for Virus Research
Approved May 2020

A new unbiased, peptidomics-based testing for hepatitis viruses identification including HCV infection. 
Hadassah Hebrew University Hospital, Jerusalem, Israel 
Approved August 2021

Genomic and phylo-epidemiological surveillance of hepatitis C virus diversity and antiviral resistance in the UK.
Public Health England
Approved September 2021

GALAD testing for the diagnosis of hepatocellular carcinoma.
University of Nottingham
Approved August 2022

Variants in HCV NS5A possibly associated with liver disease.
University of Heidelberg, Germany
Approved September 2022

Publications

To date, HCV Research UK resources have supported the publication of 28 articles listed below:

  1. Adeboyejo K, King BJ, Tsoleridis T, Tarr AW, McLauchlan J, Irving WL, Ball JK, McClure CP. 2022. Hepatitis C subtyping assay failure in UK patients born in sub-Saharan Africa: Implications for global treatment and elimination. J Med Virol doi:10.1002/jmv.28178.

  2. Ansari MA, Aranday-Cortes E, Ip CL, da Silva Filipe A, Lau SH, Bamford C, Bonsall D, Trebes A, Piazza P, Sreenu V, Cowton VM, Consortium S-H, Hudson E, Bowden R, Patel AH, Foster GR, Irving WL, Agarwal K, Thomson EC, Simmonds P, Klenerman P, Holmes C, Barnes E, Spencer CC, McLauchlan J, Pedergnana V. 2019. Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. Elife 8.

  3. Ansari MA, Pedergnana V, C LCI, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I, Smith D, Nicholson G, McVean G, Trebes A, Piazza P, Fellay J, Cooke G, Foster GR, Consortium S-H, Hudson E, McLauchlan J, Simmonds P, Bowden R, Klenerman P, Barnes E, Spencer CCA. 2017. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet 49:666-673.

  4. Aranday-Cortes E, McClure CP, Davis C, Irving WL, Adeboyejo K, Tong L, da Silva Filipe A, Sreenu V, Agarwal K, Mutimer D, Stone B, Cramp ME, Thomson EC, Ball JK, McLauchlan J. 2022. Real-world outcomes of direct-acting antiviral treatment and retreatment in United Kingdom-based patients infected with hepatitis C virus genotypes/subtypes endemic in Africa. J Infect Dis 226:995-1004.

  5. Bradshaw D, Bibby DF, Manso CF, Piorkowska R, Mohamed H, Ledesma J, Bubba L, Chan YT, Ngui SL, Carne S, Mbisa JL, Consortium S-H. 2022. Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing. Clin Microbiol Infect 28:405-409.

  6. Bradshaw D, Mbisa JL, Geretti AM, Healy BJ, Cooke GS, Foster GR, Thomson EC, McLauchlan J, Agarwal K, Sabin C, Mutimer D, Moss P, Irving WL, Barnes E, Hepatitis C Trust UK. 2019. Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. J Infect 79:503-512.

  7. Buch S, Innes H, Lutz PL, Nischalke HD, Marquardt JU, Fischer J, Weiss KH, Rosendahl J, Marot A, Krawczyk M, Casper M, Lammert F, Eyer F, Vogel A, Marhenke S, von Felden J, Sharma R, Atkinson SR, McQuillin A, Nattermann J, Schafmayer C, Franke A, Strassburg C, Rietschel M, Altmann H, Sulk S, Thangapandi VR, Brosch M, Lackner C, Stauber RE, Canbay A, Link A, Reiberger T, Mandorfer M, Semmler G, Scheiner B, Datz C, Romeo S, Ginanni Corradini S, Irving WL, Morling JR, Guha IN, Barnes E, Ansari MA, Quistrebert J, Valenti L, Muller SA, Morgan MY, Dufour JF, Trebicka J, et al. 2022. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut doi:10.1136/gutjnl-2022-327196.

  8. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WTH, MacDonald DC, Agarwal K, Foster GR, Irving WL, UK HCVR. 2016. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65:741-747.

  9. da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W, Macdonald D, Richardson P, Aldersley MA, Wiselka M, Ustianowski A, McLauchlan J, Thomson EC. 2018. Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'". J Hepatol 68:864-866.

  10. Elsheikh MEA, McClure CP, Tarr AW, Irving WL. 2022. Sero-reactivity to three distinct regions within the hepatitis C virus alternative reading frame protein (ARFP/core+1) in patients with chronic HCV genotype-3 infection. J Gen Virol 103.

  11. Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WT, MacDonald DC, Agarwal K, Hcv Research UK. 2016. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64:1224-31.

  12. Innes H, Jepsen P, McDonald S, Dillon J, Hamill V, Yeung A, Benselin J, Went A, Fraser A, Bathgate A, Ansari MA, Barclay ST, Goldberg D, Hayes PC, Johnson P, Barnes E, Irving W, Hutchinson S, Guha IN. 2021. Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. JHEP Rep 3:100384.

  13. Innes H, Nischalke HD, Guha IN, Weiss KH, Irving W, Gotthardt D, Barnes E, Fischer J, Ansari MA, Rosendahl J, Lin SK, Marot A, Pedergnana V, Casper M, Benselin J, Lammert F, McLauchlan J, Lutz PL, Hamill V, Mueller S, Morling JR, Semmler G, Eyer F, von Felden J, Link A, Vogel A, Marquardt JU, Sulk S, Trebicka J, Valenti L, Datz C, Reiberger T, Schafmayer C, Berg T, Deltenre P, Hampe J, Stickel F, Buch S. 2022. The rs429358 Locus in apolipoprotein E is associated with hepatocellular carcinoma in patients with cirrhosis. Hepatol Commun 6:1213-1226.

  14. Innes H, Walker AJ, Benselin J, Grove JI, Pedergnana V, Azim Ansari M, Lin SK, McLauchlan J, Hutchinson SJ, Barnes E, Irving WL, Guha IN, UK HCVR, Stop HCV, Consortia. 2022. Comprehensive comparative analysis of standard validated, genetic, and novel biomarkers to enhance prognostic risk-stratification in patients with hepatitis C virus cirrhosis. Clin Transl Gastroenterol 13:e00462.

  15. Johnson PJ, Berhane S, Walker AJ, Gordon FH, Ryder SD, McPherson S, Sreedharan A, Ustianowski AA, Agarwal K, Mutimer D, Kumada T, Toyoda H, Irving WL, UK HCVR. 2021. Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. J Viral Hepat 28:168-176.

  16. Karamitros T, Hurst T, Marchi E, Karamichali E, Georgopoulou U, Mentis A, Riepsaame J, Lin A, Paraskevis D, Hatzakis A, McLauchlan J, Katzourakis A, Magiorkinis G. 2018. Human Endogenous Retrovirus-K HML-2 integration within RASGRF2 is associated with intravenous drug abuse and modulates transcription in a cell-line model. Proc Natl Acad Sci U S A 115:10434-10439.

  17. Kumada T, Toyoda H, Yasuda S, Tada T, Tanaka J, Chayama K, Johnson PJ, Irving WL. 2021. Comparison of the prognosis of decompensated cirrhosis in patients with and without eradication of hepatitis C virus. Infect Dis Ther 10:1001-1013.

  18. Macken L, Gelson W, Priest M, Abouda G, Barclay S, Fraser A, Healy B, Irving W, Verma S. 2019. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort. J Med Virol 91:1979-1988.

  19. McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E, McDonald S, Wilkes B, Hutchinson SJ, Irving WL, Committee HCVRUS. 2017. Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. Int J Epidemiol 46:1391-1391h.

  20. Mecci AJ, Kemos P, Leen C, Lawson A, Richardson P, Khakoo SI, Agarwal K, Mutimer D, Rosenberg WM, Foster GR, Irving WL, UK HCVR. 2019. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Aliment Pharmacol Ther 50:204-214.

  21. Modin L, Arshad A, Wilkes B, Benselin J, Lloyd C, Irving WL, Kelly DA. 2019. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol 70:371-378.

  22. Pedergnana V, Irving WL, Barnes E, McLauchlan J, Spencer CCA. 2019. Impact of IFNL4 genetic variants on sustained virologic response and viremia in hepatitis C virus genotype 3 patients. J Interferon Cytokine Res 39:642-649.

  23. Simmonds P, Cuypers L, Irving WL, McLauchlan J, Cooke GS, Barnes E, Consortium S-H, Ansari MA. 2020. Impact of virus subtype and host IFNL4 genotype on large-scale RNA structure formation in the genome of hepatitis C virus. RNA 26:1541-1556.

  24. Smith DA, Bradshaw D, Mbisa JL, Manso CF, Bibby DF, Singer JB, Thomson EC, da Silva Filipe A, Aranday-Cortes E, Ansari MA, Brown A, Hudson E, Benselin J, Healy B, Troke P, McLauchlan J, Barnes E, Irving WL. 2021. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. J Viral Hepat 28:1256-1264.

  25. Smith DA, Fernandez-Antunez C, Magri A, Bowden R, Chaturvedi N, Fellay J, McLauchlan J, Foster GR, Irving WL, Consortium S-H, Simmonds P, Pedergnana V, Ramirez S, Bukh J, Barnes E, Ansari MA. 2021. Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. Nat Commun 12:6105.

  26. Thomson E, Ip CL, Badhan A, Christiansen MT, Adamson W, Ansari MA, Bibby D, Breuer J, Brown A, Bowden R, Bryant J, Bonsall D, Da Silva Filipe A, Hinds C, Hudson E, Klenerman P, Lythgow K, Mbisa JL, McLauchlan J, Myers R, Piazza P, Roy S, Trebes A, Sreenu VB, Witteveldt J, Consortium S-H, Barnes E, Simmonds P. 2016. Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. J Clin Microbiol 54:2470-84.

  27. Wing PAC, Jones M, Cheung M, DaSilva S, Bamford C, Jason Lee WY, Aranday-Cortes E, Da Silva Filipe A, McLauchlan J, Smith D, Irving W, Cunningham M, Ansari A, Barnes E, Foster GR. 2019. Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. Gastroenterology 157:692-704 e9.

  28. Young J, Weis N, Hofer H, Irving W, Weiland O, Giostra E, Pascasio JM, Castells L, Prieto M, Postema R, Lefevre C, Evans D, Bucher HC, Calleja JL. 2017. The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. BMC Infect Dis 17:45.